Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021 - Key vendors are GlaxoSmithKline, Merck, Novartis & Pfizer - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021" report to their offering.

The analysts forecast the global hospital acquired pneumonia drugs market to grow at a CAGR of 2.22% during the period 2017-2021.

Global Hospital Acquired Pneumonia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is combination therapy for the treatment of HAP. Monotherapy is the common treatment given for nosocomial pneumonia. However, combination therapy has sometimes been found to be more appropriate and desirable treatment.

One driver in the market is unmet demand due to lack of available treatment for MDR microorganisms. Lack of proper treatment options available for the treatment of HAP because of MDR microorganisms is a major challenge for the healthcare providers. MDR microorganisms are those microorganisms that have developed antimicrobial drugs resistance. The resistance among various microorganisms to various antimicrobial drugs has emerged as a serious threat to public health across the globe.

Key vendors

  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer

Other prominent vendors

  • Arsanis
  • AstraZeneca
  • Combioxin
  • Mylan
  • Shinogi
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical
  • The Medicines Company
  • Theravance Biopharma

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Disease overview

Part 06: Market landscape

Part 07: Pipeline analysis

Part 08: Market segmentation by drug class

Part 09: Geographical segmentation

Part 10: Decision framework

Part 11: Drivers and challenges

Part 12: Market trends

Part 13: Vendor landscape

Part 14: Key vendor analysis

Part 15: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/rcksz5/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs